Table 5 Changes in FOG-Q, PDQ 39, and UPDRS scores throughout the study

From: Parkinson’s disease medication adjustments based on wearable device information compared to other methods: randomized clinical trial

Variable

 

Visit Group, n = 54

Diary Group, n = 50

Sensor Group, n = 50

Regression analysis

Comparison

Estimate

CI

p-value

FOG-Q scores, Mean (SD)

Baseline

10.1 (6.08)

10.8 (6.73)

10.8 (6.28)

DG vs. VGa

−1.20

−2.72 to 0.33

0.123

Final

11.3 (6.12)

10.9 (6.63)

11.0 (5.62)

SG vs. VGa

−1.13

−2.64 to 0.38

0.140

p-value (Baseline vs. Final)

0.3701

0.9269

0.9992

 

PDQ-39 scores, Mean (SD)

Baseline

30.7 (15.4)

36.1 (18.4)

30.5 (16.4)

DG vs. VGb

−2.94

−7.09 to 1.21

0.163

Final

30.4 (17.8)

31.5 (17.5)

29.9 (14.8)

SG vs. VGb

0.02

−4.07 to 4.10

0.993

p-value (Baseline vs. Final)

0.9168

0.2111

0.8641

 

UPDRS-II scores, Mean (SD)

Baseline

10.2 (5.28)

12.9 (6.65)

12.7 (5.70)

DG vs. VGc

−0.74

−2.50 to 1.01

0.403

Final

9.74 (6.11)

11.2 (7.47)

13.0 (6.00)

SG vs. VGc

0.93

−0.82 to 2.68

0.295

p-value (Baseline vs. Final)

0.6606

0.2493

0.7983

 

UPDRS-III scores, Mean (SD)

Baseline

18.0 (10.4)

22.9 (12.4)

22.2 (10.0)

DG vs. VGd

0.70

−2.33 to 3.73

0.647

Final

16.4 (11.1)

21.5 (13.9)

22.1 (10.9)

SG vs. VGd

2.16

−0.86 to 5.18

0.159

p-value (Baseline vs. Final)

0.4456

0.6122

0.962

 

UPDRS-IV scores, Mean (SD)

Baseline

1.55 (1.76)

1.22 (1.76)

1.78 (1.81)

DG vs. VGe

0.01

−0.56 to 0.59

0.963

Final

1.36 (1.67)

1.25 (1.57)

1.80 (2.02)

SG vs. VGe

0.22

−0.35 to 0.79

0.441

p-value (Baseline vs. Final)

0.5798

0.9058

0.9585

 
  1. CI confidence interval, DG Diary Group, FOG-Q Freezing of Gait Questionnaire, PDQ39 the 39-item PD Questionnaire, SG Sensor Group, UPDRS unified PD rating scale, VG Visit Group.
  2. aObservations = 142, R2/R2 adjusted=0.646/0.630, AIC = 782.103.
  3. bObservations = 141, R2/R2 adjusted=0.622/0.605, AIC = 1054.381.
  4. cObservations = 146, R2/R2 adjusted=0.604/0.590, AIC = 848.489.
  5. dObservations = 147, R2/R2 adjusted=0.633/0.620, AIC = 1016.022.
  6. eObservations = 148, R2/R2 adjusted=0.350/0.322, AIC = 530.809.
  7. Model adjusted by equivalent dopaminergic dose, UPRS-II, UPDRS-III, and the corresponding variable at baseline, where applicable.
Back to article page